Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a biopharmaceutical company dedicated to developing innovative medicines that treat intractable diseases by silencing the genes that cause them. Utilizing its proprietary Targeted RNAi Molecule (TRiM™) platform, Arrowhead aims to trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. Their diverse pipeline focuses on a range of diseases, including those affecting the liver, lungs, and muscle, with several candidates in various stages of clinical development. The company actively pursues collaborations with other leading pharmaceutical companies to expand the reach and application of its technology.
The Pasadena headquarters serves as the central hub for executive leadership, corporate strategy, investor relations, business development, and oversight of global research and clinical operations.
Located in a modern office building in the heart of Pasadena, offering convenient access to local amenities and a professional environment. The facilities are designed to support corporate functions and foster collaboration.
The work culture at Arrowhead's headquarters is likely dynamic and science-driven, reflecting its focus on cutting-edge biotechnology. It emphasizes innovation, collaboration among teams, and a strong commitment to addressing unmet medical needs.
This location is pivotal for Arrowhead's strategic decision-making and global coordination of its drug development programs. Its presence in Southern California provides access to a rich talent pool and a vibrant biotech ecosystem.
While Arrowhead Pharmaceuticals' primary research, development, and corporate operations are centered in the United States (Pasadena, CA; Madison, WI; Verona, WI), its impact is global. The company conducts clinical trials in numerous countries across North America, Europe, Asia-Pacific, and other regions to evaluate its therapeutic candidates. Furthermore, Arrowhead engages in strategic licensing and collaboration agreements with international pharmaceutical partners, such as GSK, Amgen, Johnson & Johnson (Janssen), and Takeda, to develop and commercialize its RNAi therapies worldwide, extending the reach of its innovative TRiM™ platform.
177 E. Colorado Blvd., Suite 700
Pasadena
CA
USA
Address: 465 Science Dr, Madison, WI 53711, USA
Leverages Madison's strong biotech ecosystem and proximity to the University of Wisconsin-Madison, fostering scientific innovation and talent acquisition for R&D activities.
Address: 1255 Deming Way, Verona, WI 53593, USA
Provides critical in-house manufacturing capacity, ensuring quality control and supply chain management for Arrowhead's investigational medicines.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Arrowhead Pharmaceuticals' leadership includes:
Arrowhead Pharmaceuticals has been backed by several prominent investors over the years, including:
Over the past year, Arrowhead Pharmaceuticals has focused on strengthening its executive leadership, particularly in commercial and human resources, to support its transition towards potential product commercialization and continued growth. No major executive departures have been publicly announced.
Discover the tools Arrowhead Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Arrowhead Pharmaceuticals commonly utilizes the email format combining the first initial of an employee's name with their full last name, followed by '@arrowheadpharma.com'. Variations may exist, but this is a frequently observed pattern for professional communications.
[first_initial][last]@arrowheadpharma.com
Format
jdoe@arrowheadpharma.com
Example
80%
Success rate
Arrowhead Pharma Official Website • May 21, 2024
Arrowhead Pharmaceuticals announced positive interim results from the SHASTA-2 Phase 2 clinical study of plozasiran (ARO-APOC3), an investigational RNAi therapeutic for severe hypertriglyceridemia (SHTG). The data, presented at the National Lipid Association (NLA) Scientific Sessions 2024, showed significant reductions in triglycerides and other atherogenic lipoproteins....more
Arrowhead Pharma Official Website • May 9, 2024
Arrowhead Pharmaceuticals reported its financial results for the fiscal second quarter ended March 31, 2024. The company highlighted progress across its pipeline of RNAi therapeutics, including advancements in clinical trials and ongoing strategic collaborations....more
GlobeNewswire • February 6, 2024
Arrowhead Pharmaceuticals announced an exclusive license agreement with GSK for ARO-HSD (now GSK4532378), its investigational RNAi therapeutic for alcohol-related and nonalcohol-related liver diseases. Arrowhead received an upfront payment and is eligible for development, regulatory, and commercial milestones, plus royalties....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Arrowhead Pharmaceuticals, are just a search away.